year. 16 or 17 in north west wales. tomorrow evening, watch for the skies, northern ireland and scotland, could be intriguing sunsets ahead of a weather front that will be bringing rain. before it arrives, saharan dust makes ten which could be deposited onto cars for wednesday morning. more cloud and outbreaks of rain spreading southwards and eastwards, fizzling as it goes, east anglia and the south east staying dry, pretty mild here, temperatures dropping elsewhere but still above average for the time of year. into thursday, england and wales could start cloudy, misty, murky and wet, wet into friday, but by friday widespread gales are possible. matt with the latest on the weather. that is bbc news at ten on monday the 13th of february, more analysis of the main stories of the day and more besides on newsnight, 100 of the main stories of the day and more besides on newsnight,100 years of broadcasting from broadcasting housein of broadcasting from broadcasting house in cardiff
Southern england, through the Channel Islands as we reach the second half the day. The wind starts to pick up. And that rain continues to pick up. And that rain continues to move north ward as we head into thursday, turning milder, milder by day and by night, as we push towards the end of the week, with low pressure it stays windy heavy rainfall round, in the north and east, where we could see some Flooding Issues across parts of eastern scot. Stay attuned to the forecast. That is thanks stav. Its time to cross to the nations and regions for the news where you are. Goodbye. Hello and welcome to sportsday im gavin ramjaun. The Battle For Control Over Manchester United well have more on what a stake forjim ratcliffes ineos would mean for the club, and its future. Scotland celebrate qualification is sealed for next years euros without a ball being kicked. And what a weekend at the Rugby World Cup as england now face a date with champions south africa, following their dramatic win over hos
more besides on newsnight, 100 of the main stories of the day and more besides on newsnight,100 years of broadcasting from broadcasting housein of broadcasting from broadcasting house in cardiff, that is coming up on bbc two. on bbc one, we have our welsh colleague in there somewhere, plus all of our other presenters in the nations and regions ready with the nations and regions ready with the news where you are. from all of us, good night. good evening, i m tulsen tollett and this is your sports news where we start in the premier league. liverpool came out on top in a fiery merseyside derby against everton with a 2 0 win at anfield. joe lynskey was watching. in 2023 liverpool looked around for answers. they came here still without a league win this year. and nextin without a league win this year. and next in view where they are merseyside rivals. everjane had put hopein merseyside rivals. everjane had put hope in a new coach a new approach that goes for goals from set pieces.
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
OCALA, Fla., Jan. 06, 2021 AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIM’s efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms. Additional patients are in the process of being enrolled. The Company also reported it will host an investor conference call on January 12, 2020 at 11AM ET to discuss the AMP-511 trial, believed to be the first clinical trial to treat a patient with COVID-19-induced chronic fatigue-like symptoms, as well as to provide an overall status update on the Company.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed .
AIM ImmunoTech Inc.January 6, 2021 GMT
OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIM’s efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms. Additional patients are in the process of being enrolled. The Company also reported it will host an investor conference call on January 12, 2020 at 11AM ET to discuss the AMP-511 trial, believed to be the first clinical trial to treat a patient with COVID-19-induced chronic fatigue-like symptoms, as well as to provide an overall status update